Dr. Marc Ferrante of the University Hospital Leuven,
Belgium, presented during Digestive Disease Week (May 20-25) the
results of a major study that successfully demonstrated that a panel
of serological markers, in particular Glycominds Ltd.'s IBDX(TM) panel
of biomarkers, may define different outcomes for Crohn's disease
patients.
During the study, blood tests were applied on a total of 913 Crohn's disease patients using the different commercially available serological markers, that make up the IBDX(TM) panel. The markers used were: Anti Saccharomyces cerevisiae Antibodies (gASCA), Anti Chitobioside Carbohydrate Antibodies (ACCA), Anti-Laminaribioside Carbohydrate Antibodies (ALCA) and Anti-Mannobioside Carbohydrate Antibodies (AMCA) (Glycominds Ltd., Israel), and Outer Membrane Porin antibodies (Omp+) (Inova Diagnostics Inc.).
A blinded retrospective analysis of the combined score based on the number of positive results was compared to the outcome of clinical characteristics such as smoking, disease location, complications (strictures or fistulas) and the need for surgery. The results showed that specific anti-glycan serological markers are associated with severe and complicated Crohn's disease and with the need for surgery.
"The discovery of new serological markers for the diagnosis of Inflammatory Bowel Disease and for Crohn's disease stratification is fascinating and requires further investigation," said Dr. Severine Vermeire of the University Hospital Leuven, Belgium, the Principal Investigator of this study.
These anti-glycan serological markers are part of the IBDX(TM) panel which is currently available in market for the aid in the diagnosis of Inflammatory Bowel Disease and in the differential stratification of Crohn's patients. "Glycominds next plan is to repeat these results on additional patient samples so as to assist GI physicians in decision-making that will lead to better treatments," said Avinoam Dukler, CEO of Glycominds.
Glycominds is pioneering the application of novel glycan markers to clinical practice. The company is discovering, developing and commercializing simple blood tests to significantly improve treatment decisions for patients with autoimmune and inflammatory diseases. These tests allow earlier and more complete diagnosis, enabling physicians to better customize patient care and avoid unnecessary invasive procedures.
Glycominds is the developer of gMS(TM), a marker for Multiple Sclerosis that remarkably predicts, starting from the very first neurological event, if the patient will progress to Relapsing Remitting MS, as well as risk a high disease progression rate. Glycominds plans to launch this MS test through the company's own clinical labs.
Glycominds is leveraging the company's patented GlycoChip(R) technology, to rapidly discover and validate novel markers for autoimmune & inflammation, cancer indications and pandemic diseases in order to keep a continuous pipeline of high value GlycoDx(TM) products.
For more information visit www.glycominds.com.
During the study, blood tests were applied on a total of 913 Crohn's disease patients using the different commercially available serological markers, that make up the IBDX(TM) panel. The markers used were: Anti Saccharomyces cerevisiae Antibodies (gASCA), Anti Chitobioside Carbohydrate Antibodies (ACCA), Anti-Laminaribioside Carbohydrate Antibodies (ALCA) and Anti-Mannobioside Carbohydrate Antibodies (AMCA) (Glycominds Ltd., Israel), and Outer Membrane Porin antibodies (Omp+) (Inova Diagnostics Inc.).
A blinded retrospective analysis of the combined score based on the number of positive results was compared to the outcome of clinical characteristics such as smoking, disease location, complications (strictures or fistulas) and the need for surgery. The results showed that specific anti-glycan serological markers are associated with severe and complicated Crohn's disease and with the need for surgery.
"The discovery of new serological markers for the diagnosis of Inflammatory Bowel Disease and for Crohn's disease stratification is fascinating and requires further investigation," said Dr. Severine Vermeire of the University Hospital Leuven, Belgium, the Principal Investigator of this study.
These anti-glycan serological markers are part of the IBDX(TM) panel which is currently available in market for the aid in the diagnosis of Inflammatory Bowel Disease and in the differential stratification of Crohn's patients. "Glycominds next plan is to repeat these results on additional patient samples so as to assist GI physicians in decision-making that will lead to better treatments," said Avinoam Dukler, CEO of Glycominds.
Glycominds is pioneering the application of novel glycan markers to clinical practice. The company is discovering, developing and commercializing simple blood tests to significantly improve treatment decisions for patients with autoimmune and inflammatory diseases. These tests allow earlier and more complete diagnosis, enabling physicians to better customize patient care and avoid unnecessary invasive procedures.
Glycominds is the developer of gMS(TM), a marker for Multiple Sclerosis that remarkably predicts, starting from the very first neurological event, if the patient will progress to Relapsing Remitting MS, as well as risk a high disease progression rate. Glycominds plans to launch this MS test through the company's own clinical labs.
Glycominds is leveraging the company's patented GlycoChip(R) technology, to rapidly discover and validate novel markers for autoimmune & inflammation, cancer indications and pandemic diseases in order to keep a continuous pipeline of high value GlycoDx(TM) products.
For more information visit www.glycominds.com.
© 2006 Business Wire
